Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (G-202-003)

This study has been completed.
Information provided by (Responsible Party):
GenSpera, Inc. Identifier:
First received: January 18, 2013
Last updated: August 18, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: August 18, 2016